Navigation Links
Dong-A PharmTech Co., Ltd. and Dr. Falk Pharma GmbH Announce Positive Data in Portal Hypertension With Udenafil
Date:6/13/2011

SEOUL, South Korea, June 13, 2011 /PRNewswire/ -- Dong-A PharmTech Co., Ltd. and Dr. Falk Pharma GmbH announced positive results from an initial safety and efficacy portal hypertension study in man using udenafil, its new long-active phosphodiesterase inhibitor. The data was presented by the principal investigator, Prof. Wolfgang Kreisel, Department of Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, University of Freiburg, Freiburg, Germany.

In a 1-week open-label, multicenter phase 2 trial, 20 patients with portal hypertension (Child-Pugh A/B) that met the selection criteria were given a daily oral dose of one of four dose levels of udenafil. The primary efficacy endpoint was the change of hepatic venous pressure gradient (HVPG) from day 0 (pre dose) to day 6 post dose.  A total of 7 of 20 patients showed a response defined as a HVPG reduction of < 12 mmHG or by > 20% after one week of daily dosing.  In the high dose group, HVPG was lowered in 4 of the 5 patients by more than 10% after administration of study drug on day 0 or day 6.  No decrease of mean arterial blood pressure was seen in any of the four dose groups.  Standard liver biochemical tests did not change during the study and no adverse events were attributed to the study drug.

The results of this study show that the oral application of the new PDE-5 inhibitor udenafil lowers HVPG in an acute setting without any systemic cardiovascular side effects.  Effectiveness appears to be dose related.  Further study is contemplated using a placebo controlled design and a longer study duration.

About Dong-A PharmTech Co., Ltd.

Dong-A PharmTech is a late-stage pharmaceutical company incorporated in Korea, focused on the development and commercialization of udenafil worldwide excluding Korea.

About Dr. Falk Pharma GmbH .<
'/>"/>

SOURCE Dong-A PharmTech Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
2. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
3. Dong-A PharmTech Co., Ltd. Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the ... Healthcare Distribution Specialist, LLC ("HDS") are pleased to announce ... Vitamin & Sports Nutrition Expo to be held at ... Florida on July 15-17, 2012.  As part of the ...
... announced today the Clinical Laboratory Responsibility Pledge, a ... ethical business practices in the medication monitoring industry. ... adheres and to which the company challenges every ... adopt. (Logo: http://photos.prnewswire.com/prnh/20120203/LA47138LOGO ) ...
Cached Medicine Technology:Sunpeaks Ventures to Participate in ECRM Conference and Expo 2Sunpeaks Ventures to Participate in ECRM Conference and Expo 3Millennium Laboratories Announces Laboratory Responsibility Pledge 2Millennium Laboratories Announces Laboratory Responsibility Pledge 3
(Date:4/18/2014)... A group of scientists from the University of ... on Aging has found interesting new information in ... Parkinson,s disease (PD). , Published in the ... assessed cognitive function in depressed and non-depressed patients ... commonly used to treat motor symptoms of Parkinson,s ...
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2
... Expected to Achieve Strong Uptake in this ... from Decision ResourcesWALTHAM, Mass., April 30 ... research and advisory firms for pharmaceutical and ... Amgen/Wyeth/Takeda,s Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe,s Remicade, and Abbott/Eisai,s ...
... creates federal-state-local partnership to help fight domestic violence, ... $1.1 million U.S. Justice Dept. grant is fueling ... to help combat domestic violence and sexual assault ... Appellate Prosecutor,s office has hired two full-time prosecutors ...
... steroid to multiple sclerosis treatment shows promise in study ... steroid drug in combination with a multiple sclerosis (MS) ... using the MS drug alone, suggests a new study. ... relapsing-remitting MS, some patients were randomly selected to receive ...
... of the pancreas, invagination of the pancreas into the ... fistula, according to researchers at the Jefferson Pancreas, Biliary ... the Journal of the American College of Surgeons ... the gold standard for studies. , Removing the head ...
... 2008...sales up 266%, , ... Winston-Salem, ... today that it is expanding its corporate and satellite offices ... stabilization system, VerteLoc™. , , , , ,"We are essentially ...
... principles for Getting Health IT Right under the American ... the Markle Foundation hosts a forum to discuss the ... (IT) under the American Recovery and Reinvestment Act (ARRA). ... with government and policy experts to talk about how ...
Cached Medicine News:Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 2Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 3Health News:New Illinois Prosecution Unit Helps Protect Women Against Violence 2Health News:Drug Combo May Relieve MS Symptoms 2Health News:Type of connection procedure after pancreatic surgery influenced rate of pancreatic fistula 2Health News:VGI Announces Expansion to Meet Surgeon Demand for the VerteLoc&#8482; Spine Stabilization System 2Health News:Meaningful Investment of $19 Billion on Health Information Technology 2Health News:Meaningful Investment of $19 Billion on Health Information Technology 3
The Compass Commander series is engineered to provide the discriminating neurosurgeon with the same capabilities offered within the commander plus+, all in a smaller, lower-cost package....
The CRW system epitomizes simplicity, quality assurance, and versatility....
Used to negotiate tortuous vessels....
Hydrosteer wires are intended for use in the percutaneous introduction of catheters....
Medicine Products: